No Data
No Data
Shenzhen Chipscreen Biosciences (SHSE:688321) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) announced strong profits, but the stock was stagnant. Our analysis suggests that this might be because shareholders have noticed some concernin
Microchip Biotech (688321.SH): Net loss of 18.30.46 million yuan in the first quarter
Gelonghui, April 28, 丨 Microchip Biotech (688321.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 131 million yuan, an increase of 22.60% over the previous year; net profit attributable to shareholders of listed companies - 183,046 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 219.761 million yuan; and basic earnings per share - 0.0448 yuan.
Revenues Tell The Story For Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) As Its Stock Soars 26%
Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) shareholders would be excited to see that the share price has had a great month, posting a 26% gain and recovering from prior weakness. Unfor
Chipscreen Biosciences Offers Sell-Back Option for Microchip Convertible Bond Holders
Shenzhen Chipscreen Biosciences (SHA:688321) said holders of its microchip convertible bonds will have the option to sell back their bonds to the company at 100.49 yuan per unit, according to a filing
Individual Investors Invested in Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) Copped the Brunt of Last Week's CN¥461m Market Cap Decline
Key Insights Significant control over Shenzhen Chipscreen Biosciences by individual investors implies that the general public has more power to influence management and governance-related decisions
Microchip Biotech (688321.SH): Application for clinical trial of Theoroni capsules to treat pancreatic cancer accepted
Gelonghui, April 9 | Microchip Biotech (688321.SH) announced that the company and its wholly-owned subsidiary Chengdu Microchip Pharmaceutical Co., Ltd. recently received an “Notice of Acceptance” issued by the State Drug Administration for the registration of clinical trials of domestically produced drugs, and the clinical trial application for the treatment of pancreatic cancer with Theoroni capsules was accepted.
No Data